Published in Blood Weekly, August 27th, 2009
The LOI, which is subject to the execution of a definitive agreement, contemplates the providing by BMSN of facilities and infrastructure to be utilized by both parties for the development of immuno-therapeutic treatments for cancer. Initially, BMSN and Therinject intend to focus on the veterinary market, looking to treat animals with tumors while...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.